TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07846033: A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities

Sponsor: Viking Therapeutics, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 56 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07846033 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07846033 Rescue Dossier →